Company Overview
OKYO Pharma Limited operates as a clinical-stage biopharmaceutical company focused on developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain within the United Kingdom. The company's primary pipeline asset, urcosimod, is currently advancing through Phase II clinical trials specifically for the treatment of dry eye disease. This entity functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning it to address significant unmet medical needs in ophthalmology. OKYO Pharma Limited is a small-scale enterprise with a market capitalization of $80.29M, employing just four individuals, and it does not currently report annual revenue figures. The extremely small market cap and lack of reported revenue indicate that the company is in an early-stage development phase where valuation is driven by potential clinical outcomes rather than current financial performance or established market share.
Financial Health
The company reports no annual revenue (TTM), a net income of $-4,613,341, and an EBITDA of $-6,252,605, reflecting the heavy burn rate typical of pre-revenue biotechnology firms. The absence of revenue while incurring substantial net losses highlights a cost structure dominated by research and development expenses rather than operational overhead or cost of goods sold. Free cash flow stands at $-3,001,427, indicating that the company is consuming its cash reserves to fund clinical trials and operational expenditures without generating positive cash inflows from sales. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which signifies that the company has not yet achieved a revenue base large enough to calculate meaningful profitability ratios or sustain operations without external capital injection. On the balance sheet, the company holds $4.22M in cash against a debt level of $185,795, yet the debt-to-equity ratio is listed as N/A, suggesting that equity values may be insufficient or negative to support a standard leverage calculation. The current ratio of 0.58 indicates that the company's current assets are less than its current liabilities, pointing to potential short-term liquidity challenges if cash burn continues at the current pace. Return on Assets is -104.6%, while Return on Equity is N/A, revealing that management is utilizing assets to generate significant negative returns relative to the asset base and that traditional measures of management effectiveness based on shareholder equity are not applicable due to the company's financial structure.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is reported as -7.65, implying that the market anticipates continued negative earnings in the near future rather than a transition to profitability. The price-to-book ratio stands at -17.19, a negative figure that indicates the market is valuing the company below its book value, often seen in distressed or pre-revenue biotech firms where assets may not fully reflect intellectual property potential. Price-to-sales and EV/EBITDA metrics are also negative or unavailable (EV/EBITDA is -8.76), suggesting that traditional valuation multiples are distorted by the company's lack of revenue and negative cash flows. The stock has traded between a 52-week low of $1.03 and a 52-week high of $3.35, meaning the current price sits within a range defined by these historical extremes, though the specific current price relative to the high cannot be calculated without live data, the beta provides volatility context. With a beta of -0.15, the stock exhibits negative correlation to the broader market, meaning it tends to move inversely to market trends, a characteristic often found in small-cap biotechnology stocks with idiosyncratic risk profiles.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, as the company has not yet generated positive revenue streams to establish a historical growth trajectory. Since the company is a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders, instead retaining all available capital to fund its clinical development pipeline. The 0.0% payout ratio is mathematically consistent with the company's negative net income, confirming that no dividends can be sustained or paid out of earnings. Consequently, the overall growth and income profile is characterized by a total reliance on capital markets for funding growth, with no current income generation for shareholders and no historical growth data to analyze against revenue.